Saltar al contenido
Merck

SML1133

SGC-CBP30

≥98% (HPLC)

Sinónimos:

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C28H33ClN4O3
Número CAS:
1613695-14-9
Peso molecular:
509.04
UNSPSC Code:
51111800
PubChem Substance ID:
329825669
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

SMILES string

CC1=C(C(C)=NO1)C2=CC=C3C(N=C(CCC4=CC=C(OC)C(Cl)=C4)N3C[C@@H](N5CCOCC5)C)=C2

InChI

1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1

InChI key

GEPYBHCJBORHCE-SFHVURJKSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Categorías relacionadas

Application

SGC-CBP30 has been used in immunofluorescence, to study the regulation of HAT (histone acetyltransferase) activity. It has also been used to abolish synergistic gene expression induced by transcription factors in hepatocytes.

Biochem/physiol Actions

SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.021 and 0.038 μM, respectively). SGC-CBP30 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please visit the SGC-CBP30 probe summary on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300.
SGC-CBP30 might serve as a therapeutic agent in treating cancer. In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 is found to decrease immune cell production of T helper cell 17 and other pro-inflammatory cytokines.

Features and Benefits

SGC-CBP30 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Other Notes

SGC-CBP30 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the SGC-CBP30 probe summary on the Chemical Probes Portal website.

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000219413
0000219413
0000173884
0000165489
0000173884

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Transcription factor dimerization activates the p300 acetyltransferase
Ortega E, et al.
Nature, 1-1 (2018)
Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou NH, et al.
Current Opinion in Chemical Biology, 33, 58-66 (2016)
Epigenetic Targets in Drug Discovery, 144-144 (2018)
Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading.
Goldstein I, et al.
Nature Communications, 8(1), 1849-1849 (2017)
Irena Hlushchuk et al.
ACS chemical neuroscience, 12(13), 2273-2279 (2021-06-11)
Neurodegenerative diseases are associated with failed proteostasis and accumulation of insoluble protein aggregates that compromise neuronal function and survival. In Parkinson's disease, a major pathological finding is Lewy bodies and neurites that are mainly composed of phosphorylated and aggregated α-synuclein
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico